Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.

Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM.

Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.

PMID:
30013182
2.

In utero nanoparticle delivery for site-specific genome editing.

Ricciardi AS, Bahal R, Farrelly JS, Quijano E, Bianchi AH, Luks VL, Putman R, López-Giráldez F, Coşkun S, Song E, Liu Y, Hsieh WC, Ly DH, Stitelman DH, Glazer PM, Saltzman WM.

Nat Commun. 2018 Jun 26;9(1):2481. doi: 10.1038/s41467-018-04894-2.

3.

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.

Lu Y, Liu Y, Oeck S, Glazer PM.

Mol Cancer Res. 2018 Jun 22. doi: 10.1158/1541-7786.MCR-17-0637. [Epub ahead of print]

PMID:
29934325
4.

PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF.

Sulkowski PL, Scanlon SE, Oeck S, Glazer PM.

Mol Cancer Res. 2018 Aug;16(8):1241-1254. doi: 10.1158/1541-7786.MCR-17-0581. Epub 2018 May 8.

PMID:
29739874
5.

Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing.

Ricciardi AS, Quijano E, Putman R, Saltzman WM, Glazer PM.

Molecules. 2018 Mar 11;23(3). pii: E632. doi: 10.3390/molecules23030632. Review.

6.

The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.

Kim H, Lin Q, Glazer PM, Yun Z.

Breast Cancer Res. 2018 Mar 6;20(1):16. doi: 10.1186/s13058-018-0944-8.

7.

Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma.

Scanlon SE, Hegan DC, Sulkowski PL, Glazer PM.

Oncotarget. 2017 Dec 19;9(4):4647-4660. doi: 10.18632/oncotarget.23470. eCollection 2018 Jan 12.

8.

Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities.

Quijano E, Bahal R, Ricciardi A, Saltzman WM, Glazer PM.

Yale J Biol Med. 2017 Dec 19;90(4):583-598. eCollection 2017 Dec. Review.

9.

Anti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy.

Gupta A, Quijano E, Liu Y, Bahal R, Scanlon SE, Song E, Hsieh WC, Braddock DE, Ly DH, Saltzman WM, Glazer PM.

Mol Ther Nucleic Acids. 2017 Dec 15;9:111-119. doi: 10.1016/j.omtn.2017.09.001. Epub 2017 Sep 12.

10.

A cell-penetrating antibody inhibits human RAD51 via direct binding.

Turchick A, Hegan DC, Jensen RB, Glazer PM.

Nucleic Acids Res. 2017 Nov 16;45(20):11782-11799. doi: 10.1093/nar/gkx871.

11.

Nickel induces transcriptional down-regulation of DNA repair pathways in tumorigenic and non-tumorigenic lung cells.

Scanlon SE, Scanlon CD, Hegan DC, Sulkowski PL, Glazer PM.

Carcinogenesis. 2017 Jun 1;38(6):627-637. doi: 10.1093/carcin/bgx038.

12.

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.

Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS.

Sci Transl Med. 2017 Feb 1;9(375). pii: eaal2463. doi: 10.1126/scitranslmed.aal2463.

13.

DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy.

Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB.

Mol Cancer Res. 2017 Mar;15(3):269-280. doi: 10.1158/1541-7786.MCR-16-0227-T. Epub 2017 Jan 10.

14.

In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery.

Bahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM.

Nat Commun. 2016 Oct 26;7:13304. doi: 10.1038/ncomms13304.

15.

miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair.

Czochor JR, Sulkowski P, Glazer PM.

Mol Cancer Res. 2016 Apr;14(4):363-73. doi: 10.1158/1541-7786.MCR-15-0399. Epub 2016 Feb 5.

16.

Nanotechnology for delivery of peptide nucleic acids (PNAs).

Gupta A, Bahal R, Gupta M, Glazer PM, Saltzman WM.

J Control Release. 2016 Oct 28;240:302-311. doi: 10.1016/j.jconrel.2016.01.005. Epub 2016 Jan 8. Review.

17.

DNA-dependent targeting of cell nuclei by a lupus autoantibody.

Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE.

Sci Rep. 2015 Jul 9;5:12022. doi: 10.1038/srep12022.

18.

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.

Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM.

Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26.

19.

Tumor suppressor p53 stole the AKT in hypoxia.

Yun Z, Glazer PM.

J Clin Invest. 2015 Jun;125(6):2264-6. doi: 10.1172/JCI82058. Epub 2015 May 11.

20.

Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.

Scanlon SE, Glazer PM.

DNA Repair (Amst). 2015 Aug;32:180-9. doi: 10.1016/j.dnarep.2015.04.030. Epub 2015 May 1. Review.

Supplemental Content

Loading ...
Support Center